Axona is a prescription medical food
intended for the clinical dietary management of the metabolic processes associated with mild to moderate Alzheimer's disease.
Axona should be used with caution in patients who are at risk for ketoacidosis, for example, patients with a history of alcohol abuse and poorly controlled diabetics; or those who have a history of inflammation of the gastrointestinal system, metabolic syndrome, and/or renal dysfunction. Axona contains caseinate and whey (dairy), and lecithin (soy).
CONTAINS: MILK AND SOY.
Please see full prescribing information at www.about-axona.com
*Based on a randomized, double-blind, placebo-controlled, 90-day, phase IIb trial.
Henderson ST. Ketone bodies as a therapeutic for Alzheimer's disease. Neurotherapeutics
. 2008;5(3):470-480. 2.
National Institute on Aging.
Alzheimer's disease [fact sheet]. http://www.nia.nih.gov/sites/default/files/alzheimers_disease_fact_sheet_0.pdf. Reprinted September 2012. Accessed December 10, 2012.3.
Henderson ST, Vogel JL, Barr LJ, et al. Study of the ketogenic agent AC-1202 in mild to moderate Alzheimer's disease: a randomized, double-blind, placebo-controlled, multicenter trial. Nutr Metab (Lond).
Reger MA, Henderson ST, Hale C, et al. Effects of β-hydroxybutyrate on cognition in memory-impaired adults.Neural Biol Aging
. 2004;25(3): 311-314.
Costantini LC, Barr LJ, Vogel JL, Henderson ST. Hypometabolism as a therapeutic target in Alzheimer's disease.BMC Neurosci.
Accera, Axona, and the Axona logo are trademarks or registered trademarks of Accera, Inc.
Patents issued: USP 6,835,750, EP 1292294, and JP 3486778; and patents pending.
© 2013 Accera, Inc. All rights reserved. AC-13-383 02/13